Author:
Batista Cynthia Julia Braga,Correa Renato Girade,Evangelista Livia Ramalho,Fleck Karen,Silva Leandro,Renaud Francoise,Vitoria Marco,Doherty Meg,Benzaken Adele Schwartz
Publisher
Ovid Technologies (Wolters Kluwer Health)
Reference5 articles.
1. Dolutegravir plus abacavir/lamivudine for the treatment of HIV-1 infection in antiretroviral therapy-naive patients: week 96 and week 144 results from the SINGLE randomized clinical trial;Walmsley;J Acquir Immune Defic Syndr,2015
2. Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naïve HIV-1-positive individuals: 96 week results from FLAMINGO;Molina;J Int AIDS Soc,2014
3. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial;Raffi;Lancet Infect Dis,2013
4. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study;Cahn;Lancet,2013
5. Clinical effectiveness of dolutegravir in the treatment of HIV/AIDS;Taha;Infect Drug Resist,2015
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献